Wednesday's coverage of doctor pay roiled physicians who say the CMS data set oversimplifies payment information and skews reality.
Phase-II results indicate Merck's all-in-one HCV oral could put pressure on Gilead.
Facts tucked among the 9.2 million lines of data: 2% of doctors account for around 25% of Medicare billing.
Express Scripts said treatments for diabetes are the most expensive of the traditional medications, while specialty drugs are eating up a significant portion of total drug spend.
Researchers found a correlation between patients feeling involved and how well they stick—if they stick—to their medication regimens.
Phase-III results prompted the drugmaker to pursue a third-quarter filing.
Analysts say the Indianapolis, IN, drugmaker's Phase-I results show CDK 4/6 inhibitors will have a role in breast cancer treatment and that Pfizer's palbociclib will not clear the field.
Sunday's data readout has divided the Street between the enthusiastic and the disappointed. The key reason: progression-free survival gains were not as high as anticipated.
The ACA has spurred double-digit increases in demand for pharmaceuticals, new data suggest.
The drugmaker saw positive results in demonstrating LDL reductions in Japanese patient populations.
Detailed Phase-III results from several PCSK9 candidates confirm the clinical ability of the newest class of cholesterol-lowering treatments.
Merck has broadened its analytics approach to include team-ups with a slate of organizations at the intersection of Big Data and health IT.
A rival's late-stage trial results suggest the pain med may have a short market life. The key: an FDA division head's documented willingness to overturn the approval should another pain option surface.
A report of over 270,000 US medical sites signals that EHR adoption is no longer a luxury reserved for hospitals and health systems.
Pfizer hit its endpoints for preventing pneumonia among the elderly, but the data may not be robust enough to spur vaccination.
Express Scripts notes that these prescriptions may not, in fact, be for ADHD.
Bayer and Amgen's Onyx subsidiary announce an oncology drug failed a Phase-III trial goal among liver cancer patients.
A survey of patients found greater prescription drug adherence among patients who received a free 30-day sample in addition to a prescription.
@openFDA and its related website launched February 27.
Data presented at a conference yesterday suggest AbbVie's all-oral regimen may be more effective than Gilead's at curing the virus in certain patients, but will it confer an edge?
The drugmaker says researchers will be able to view patient-level data and promises less jargon-filled summaries by year-end.
The new label will reflect the RA pill's superiority to methotrexate and placebo in inhibiting the progression of structural joint damage.
Phase-III results, top-lined today, show Lilly's investigational GLP-1 drug is well-positioned to eat into the multi-billion-dollar diabetes market now dominated by Novo Nordisk.
The drugmaker revealed efficacy data that analysts say could prompt the health agencies to emphasize adult vaccination.
The drugmaker was scant on details, but Phase-III ramucirumab results among non-small cell lung cancer patients showed increased overall and progression-free survival vs. placebo.
A report published by JAMA indicated that online reviews sway a percentage of patients, but that personal recommendations hold more weight.
The school will act as an independent panel for the drug maker, reviewing requests from investigators for access to anonymized, clinical-trial data.
A young company is hoping its analytics platform can help doctors and pharma figure out who's going to stop taking their medication, and get them back on track.
Positive results from a Phase-III trial edge Amgen's evolocumab closer to approval, though it's still behind rivals in the PCSK9 race.
The data and analytics giant is looking to launch an IPO. The company, which is the subject of an antitrust suit, said in its prospectus that it anticipates future acquisitions.
Mid-stage data show the drug, romosozumab, was associated with significant increases in bone mineral density compared to Lilly's Forteo and off-patent Fosamax.
Our year-end list captures the 10 that sparked heaviest interest.
Kalydeco failed to hit its primary endpoint of significantly improving lung function in a subset of CF patients, but some did show a benefit.
Sovaldi is already approved for most patients with HCV, but its marketer may have earned itself some breathing room against rivals in the next stage of the all-oral hep. C arms race.
A recent poll shows a strong desire among web-savvy patients to play a more active role in medical research.
Sanofi top-lined positive clinical data today from its investigational basal insulin, as it seeks to defend its position in this fast-growing segment.
Research suggests ADHD is becoming a regular fixture in adolescence. At the same time, publishers and startups have developed increasingly complex tools to separate patients from abusers.
A poll indicates new cholesterol guidelines won't shake up the statin market in 2014.
A study points out barriers to e-prescribing pharma products and shows how doctors rate various EHRs.
New results from its Phase II safety trial show the LDL-cholesterol lowerer was not associated with a major increase in adverse events vs. standard of care.
Most patients would advise today's FDA Lemtrada panel to allow doctors to gauge the drug's risk-benefit profile, although there was strong sentiment on either side of the issue.
An investigational cardiovascular heart drug failed to reduce the risk of heart attack or stroke, a miss which some on Wall Street say raises questions about the drugmaker's ability to deliver in late-stage trials.
Safety reviewers' reservations about the MS drug's risk profile, unveiled in briefing documents ahead of an ad-com meeting, suggest it won't be smooth sailing for the drug in the US.
Data released at the Boston meeting of the American Association for the Study of Liver Diseases hints at an upcoming Gilead-Merck brawl.
Researchers found that most healthcare apps have limited functionality, don't serve patients with multiple needs, and taper off when support is needed most. No wonder adoption is low.
Researchers say the drug class could be linked to a lower autoimmune risk among diabetics.
The AAP says greater access and education are critical in curbing STIs.
It was a 15-0 vote for Gilead's sofosbuvir in hep. C. The expedited PDUFA date: Dec. 8. Janssen's simeprivir was endorsed the day before.
Smartphone users, while in the exam room, are more apt to be in "switch mentality," a study finds.
Word came of Breakthrough Designation for an HCV hopeful, a day after a hiccup in a heart drug trial.
A report says oncologists may be using GSK's Tafinlar and Mekinist together in a non-FDA approved combination therapy.
On Monday Regeneron reported more positive Ph. III data for its wet AMD/macular edema drug Eylea (aflibercept).
In schizophrenia, non-compliance can be disastrous. Do depot drugs really make a difference for patients?
An analyst notes that early Phase III results in a psoriasis clinical trial could change the drug's efficacy profile. It could also fill out the financial potential of a standalone innovative unit, should Pfizer divide.
Five percent of the patient population accounts for 50% of US healthcare costs, one deep dive shows. A major problem: access to medical care.
Recent studies underscore a need for greater engagement in multicultural communities.
Attendance by physicians crept up in 2012, said the trade group HCEA, but overall turnout was flat, likely because exhibitors brought less personnel along to meetings.
A study shows consumers are increasingly pleased with retail pharmacies, compared to mail order pharmacies, which are often considered a key means of driving adherence and lowering healthcare coverage costs.
The partnership seeks to improve medication adherence through predictive analytics.
An upcoming leadership summit is devoted to exploring whether health social media is driving meaningful change, as well as new ways to engage with health activists.
How potential alignment between drug companies and physicians, via the EHR, could extend brand reach.
Doctors shared their information preferences with CMI/Compas, revealing ways marketers can better pace their communications to max out channels.
Researchers says growth will average 5.8% a year between 2012 and 2022. They also anticipate generics will hit a leveling-off point that will drive average Rx prices upwards
Pharmacists are surprisingly open to rep visits, are often online at work, and are making slightly more drug recommendations than the year before, findings show.
Researchers say using additional data points offers greater insight into patient-adherence patterns.
Researchers surveying 21 Long Island mammography centers found that women do not know their risk.
A good percentage of consumers are open to visiting a pharmaceutical company website, an online survey shows, despite a persistent undercurrent of distrust for industry.
For women suffering from breast cancer, online tools appeared to be helpful in battling depression, a randomized trial showed.
Re-Mission, the video simulation known to change young patients' attitudes toward cancer, is in its second iteration. And one big drug maker has added its backing.
The Centers for Disease Control and Prevention profiles the typical sleep aid user, and finds that eight hours does not mean consumers are sleeping without help.
Sales may be rising, but a new study finds current psoriasis therapies leave room for improvement. Over half of patients said they want better options.
Despite a gradual loss from generics, new treatments are expected to keep sales trending upward
The FDA approved GlaxoSmithKline's second quadrivalent flu vaccine, but a CVS study indicates that consumers are big fans of the vaccination, as long as they aren't the ones rolling up their sleeves.
Data show doctors are increasingly leaning on Regeneron's Eylea over Roche's Lucentis, as the two battle for share of the wet-AMD market.
Early sales of NPS's Gattex have soared, while those of Protalix's Elelyso have been sluggish, underscoring the challenges of rare-disease launches.
The state's first patient portal has officially entered development, and the e-health firm leading the effort said that a former WebMD executive joined its board.
Sanofi named in China corruption probe; GlaxoSmithKline starts a venture capital fund; and European non-profit AllTrials outlines its transparency goals
Oncologists have the most restrictive access policies, a study shows for the second year in a row. But it's not impossible to book face time with these clinicians.
Proteus Digital Health's ingestible sensor shows utility as an adherence tool for those on psych meds, a study suggests.
The CDC says HPV vaccination rates are not improving. The latest data comes just as a recent report shows the vaccine cannot only help fend off cervical cancer, but throat cancers as well.
A new survey of doctors reveals how much they know (or don't) about the looming launch of healthcare exchanges.
Last year, a wave of new products brought the industry succor as it awaits the full impact of the patent cliff on blockbuster brands. But companies should brace for contraction.